written on 14.05.2014

Blockbuster sales of Insys painkiller raise suspicions of off-label marketing


When Insys Therapeutics won approval for its new narcotic painkiller, Subsys, in 2012, few predicted the product would find much of a market, because the FDA limited its use to cancer patients who were already on powerful painkillers. But in 2013, the product raked in $96 million in sales, and the company's stock price quintupled to $25 a share.